ISPE-Risk MaPP, ICH Quality guidelines, EU GMP, and EMA guidance recommends a risk-based decision making in the pharmaceutical manufacturing. When different medicinal products are produced in shared facilities, the potential for cross-contamination is a concern. Medicinal products provide a benefit to the intended patient or target animal; however as a cross contaminant, they provide no benefit to the patient or target animal and may even pose a risk. Hence, the presence of such contaminants should be managed according to the risk posed which in turn are related to levels that can be considered safe for all populations. To this end, health based limits through the derivation of a safe threshold value should be employed to identify the risks posed. The derivation of such a threshold value (e.g. permitted daily exposure (PDE) or threshold of toxicological concern (TTC) should be the result of a structured scientific evaluation of all available pharmacological and toxicological data including both non-clinical and clinical data. PDE is a substance-specific dose that is unlikely to cause an adverse effect if an individual is exposed at or below this dose every day for a lifetime. It is synonymous to ADE (Acceptable Daily Exposure). PDE is a reflection of toxic potential of the compound; higher the PDE lower is the toxic potential. PDE is derived by a toxicologist from a structured scientific evaluation of relevant data.